Snapshot

MassBio.us/Industry-Snapshot





2020 Industry Snapshot



Industry Employment	2
Massachusetts Biopharma Industry Employment	
One Year Biotech Research & Development Job Growth	4
Largest Biopharma Industry Employers in Massachusetts	5
Biopharma Economic Impact, 2019	
Life Sciences Lab Inventory Growth	
Industry Geography	
Investment in the Industry	9
Top NIH-Funded States: by Total Funding and Per Capita, 2019	
Top NIH-Funded Independent Hospitals, 2019	
Top Massachusetts NIH-Funded Higher Education and Research Institutes, 2019	
Venture Capital Investment: Biopharma	
Top Venture Capital Financings in Massachusetts, 2019	14
Top Venture Capital Financings in Massachusetts, 2020 (Q1&2)	
Location of Venture Capital Backed Companies, 2019 in \$ millions	
Massachusetts IPOs 2019	
Massachusetts IPOs 2020 (Q1&2)	
Location of Companies with IPOs and Total Amount Raised, 2019 in \$ millions	
Drug Development Pipeline	20
Massachusetts Drug Development Pipeline	21
Massachusetts Pipeline by Therapeutic Area	
Massachusetts Pipeline by Medical Indication (Top 25)	
Changing the Lives of Patients	
Appendix / What's in a Number?	
About Us	
Contact Information	27


Industry Employment

Massachusetts Biopharma Industry Employment



Industry jobs grew by **94%** in the last 15 years adding over 38,000 jobs, and by **45%** in the last 10 years adding over 24,500 jobs.

In 2019, biopharma employment grew at **7.7%**, the fastest year-over-year rate since 2007.




Source: Privately owned companies, U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)



One Year Biotech Research & Development Job Growth



Massachusetts biotech R&D jobs grew by 18% last year alone, to over 46,000.



Source: Privately owned companies, U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW)



Largest Biopharma Industry Employers in Massachusetts



Takeda is the largest biopharma employer in Massachusetts.


Rank	Company	Employees	Rank	Company	Employees
1	Takeda	4,927	13	Bristol Myers Squibb	1,035
2	Sanofi	4,200	14	Alnylam	1,000
3	Biogen	2,446	15	Moderna	850
4	Novartis	2,400	16	Alkermes	820
5	Pfizer	2,100	17	Merck	706
6	Vertex	1,957	18	bluebird bio	700
7	Charles River Laboratories	1,715	19	Sarepta	607
8	MilliporeSigma	1,700	20	Amgen	600
9	Parexel International	1,220	20	AstraZeneca	600
10	Foundation Medicine	1,139	22	Sunovion Pharmaceuticals	590
11	AbbVie	1,090	23	Tesaro, A GSK Company	560
12	EMD Serono	1,047	24	Agios	536

Sources: MassBio Membership Reports & Surveys; Boston Business Journal Book of Lists, 2020



Biopharma Economic Impact, 2019


Industry Employment





Life Sciences Lab Inventory Growth






Sources: Colliers and CBRE





Industry Geography







Investment in the Industry


Top NIH-Funded States: by Total Funding & Per Capita, 2019

Investment in the Industry

Just under 10% of all NIH funding went to Massachusetts organizations in 2019.

Total NIH Funding

State	Funding	Number of Awards	
California	\$4,591,581,664	8,558	
Massachusetts	\$3,024,098,902	5,548	
New York	\$2,891,776,354	5,681	
Pennsylvania	\$1,944,017,304	3,848	
Maryland	\$1,920,138,523	2,621	
North Carolina	\$1,589,742,045	2,557	
Texas	\$1,370,180,699	3,056	
Washington	\$1,135,332,133	1,747	
Illinois	\$1,012,456,813	2,200	
Ohio	\$883,089,814	1,899	
US	\$30,885,907,765	59,528	



Source: NIH, Research Portfolio Online Reporting, U.S. Census Bureau



Top NIH-Funded Independent Hospitals, 2019

Investment in the Industry

Three of the top four NIH-funded independent hospitals are in Massachusetts.

Massachusetts receives **54% of all NIH** funding to independent hospitals.

Please note: NIH lists university-operated hospitals separately.

Organization	City	State	Awards	Funding
Massachusetts General Hospital	Boston	MA	959	\$499,645,254
Brigham and Women's Hospital	Boston	MA	567	\$338,400,990
Vanderbilt University Medical Center	Nashville	TN	506	\$284,934,924
Boston Children's Hospital	Boston	MA	375	\$196,100,744
Children's Hospital of Philadelphia	Philadelphia	PA	253	\$163,022,306
Dana-Farber Cancer Institute	Boston	MA	252	\$159,798,479
Cincinnati Children's Hospital Medical Center	Cincinnati	ОН	307	\$149,617,325
Beth Israel Deaconess Medical Center	Boston	MA	238	\$129,999,391
St. Jude's Children's Research Hospital	Memphis	TN	124	\$105,947,511
Seattle Children's Hospital	Seattle	WA	153	\$89,766,004
Cedars-Sinai Medical Center	Los Angeles	CA	152	\$70,753,307
New York State Psychiatric Institute	New York	NY	118	\$65,150,157
Boston Medical Center	Boston	MA	79	\$57,660,481
McLean Hospital	Belmont	MA	98	\$52,836,845
National Jewish Health	Denver	со	66	\$42,625,632
Roswell Park Cancer Institute Corporation	Buffalo	NY	68	\$37,844,503
Rhode Island Hospital	Providence	RI	74	\$35,351,062
Henry Ford Health System	Detroit	MI	44	\$32,254,098
Children's Hospital of Los Angeles	Los Angeles	CA	48	\$26,729,651
Massachusetts Eye and Ear Infirmary	Boston	MA	53	\$26,066,533
Children's Hospital of Los Angeles	Los Angeles	CA	41	\$22,295,828
Tufts Medical Center	Boston	MA	41	\$20,654,118

Source: NIH, Research Portfolio Online Reporting



Top MA NIH-Funded Higher Education & Research Institutes, 2019

Investment in the Industry

Massachusetts centers of Higher Education and Research Institutes received \$1.38 billion in 2019.

Organization	Awards	Funding
Harvard Medical School	374	\$195,688,539
Boston University Medical Campus	299	\$169,486,320
University of Massachusetts Medical School	345	\$155,485,455
Broad Institute	101	\$153,509,968
Harvard School of Public Health	165	\$133,377,748
Massachusetts Institute of Technology	245	\$112,793,279
Harvard University	152	\$86,228,374
Tufts University Boston	132	\$56,884,130
Boston University (Charles River Campus)	143	\$49,538,233
Northeastern University	83	\$33,098,921
University of Massachusetts Amherst	103	\$32,281,975
Brandeis University	80	\$31,728,052
Boston College	42	\$17,482,746
Joslin Diabetes Center	32	\$13,966,352
Schepen Eye Research Insitiute	31	\$11,860,244


Source: NIH, Research Portfolio Online Reporting

Venture Capital Investment: Biopharma

Investment in the Industry

Venture capital investment in Massachusetts biopharma companies was \$3.1 billion in 2019.

In the first two quarters of 2020, Massachusetts biopharma companies raised **\$2.1 billion.**



Source: PwC Money Tree Report Biopharma includes biotechnology, drug discovery, drug development, and pharmaceuticals/drugs.

Top Venture Capital Financings in Massachusetts, 2019

Investment in the Industry

Anthos Therapeutics raised the largest financing round in 2019, totaling **\$250 million**, followed by ElevateBio at **\$150 million.**

Company	Financing (\$ million)	Investment Round
Anthos Therapeutics	\$250	Series Undisclosed
ElevateBio	\$150	Series A
Beam Therapeutics	\$135	Series B
FORMA Therapeutics	\$100	Series D
eGenesis	\$100	Series B
Black Diamond Therapeutics	\$85	Series C
Black Diamond Therapeutics	\$85	Series B
OncologiE	\$80	Series B
Oncorus	\$80	Series B
Arrakis Therapeutics	\$75	Series B
Inozyme Pharma	\$67	Series A
Ribon Therapeutics	\$65	Series B
Gelesis	\$63	Series Undisclosed
Imara	\$63	Series B
Frequency Therapeutics	\$62	Series C

Source: EvaluatePharma[®], July 2020 Note: Excluding PIPE numbers.

Top Venture Capital Financings in Massachusetts, 2020 (Q1&2)

Investment in the Industry

Massachusetts biopharma companies had a strong start to 2020, led by Atea Pharmaceuticals with a **\$215 million D round.**

Company	Financing (\$ million)	Investment Round
Atea Pharmaceuticals	\$215	Series D
ElevateBio	\$170	Series B
C4 Therapeutics	\$150	Series B
Affinivax	\$120	Series B
Generation Bio	\$110	Series C
Akouos	\$105	Series B
Kymera Therapeutics	\$102	Series C
Xilio Therapeutics	\$101	Series B
Cullinan Oncology	\$99	Series B
Checkmate Pharmaceuticals	\$85	Series C


Source: EvaluatePharma[®], July 2020 Note: Excluding PIPE numbers.



Location of Venture Capital Backed Companies, 2019 in \$ millions

Investment in the Industry

Cambridge-based biopharma companies received **59%** of all biotech venture investment in the state.



Source: EvaluatePharma®, July 2020



Massachusetts IPOs 2019

Investment in the Industry



Note: Figures refer to "offer amounts" (investment secured) at time of IPO. Source: Nasdaq.com



Massachusetts IPOs 2020 (Q1&2)

Investment in the Industry

There have been **7 IPOs** from Massachusetts biotech companies in the first half of 2020, rasing an average of **\$187 million.**

33% of all US-based biotech IPOs in the first half of 2020 were from Massachusetts companies.





XKOUOS \$212 MM

21 MANA

generation bio \$200 MM



\$100 MM



Beam

\$207 MM

\$278 MM

Note: Figures refer to "offer amounts" (investment secured) at time of IPO. Source: Nasdaq.com



Location of Companies with IPOs and Total Amount Raised, 2019 in \$ millions

Investment in the Industry

In 2019, 64% of all Massachusetts biotech companies that went public were located outside of Cambridge, raising a cumulative \$676 million.



Source: EvaluatePharma[®], July 2020



Drug Development Pipeline

Massachusetts Drug Development Pipeline

Drug Development Pipeline


The Massachusetts 1052 drug development • 2,056 MA Drug Candidates^{*} pipeline includes • 12% of US Pipeline 16 candidates pending FDA • 6% of Global Pipeline approval. 486 389 101 16 Pre-clinical Filed Phase I Phase II Phase III

Only Massachusetts-headquartered company pipelines are included. Source: EvaluatePharma®, July 2020



Massachusetts Pipeline by Therapeutic Area

Drug Development Pipeline



Only Massachusetts-headquartered company pipelines are included. Source: EvaluatePharma®, July 2020



Massachusetts Pipeline by Medical Indication (Top 25)

Drug Development Pipeline

Massachusetts researchers are currently researching and developing products for patients with over **370 different medical indications.**

Medical Indication	Number of Investigational Drugs	% of all Investigational Drugs
Solid tumour indications	166	8.12%
General cancer indications	115	5.63%
Other neurological indications	50	2.45%
Undisclosed	48	2.35%
Other immune indications	42	2.05%
Alzheimer's disease	34	1.66%
Cystic fibrosis (CF)	34	1.66%
Non-small cell lung cancer (NSCLC)	32	1.57%
Duchenne muscular dystrophy	30	1.47%
General blood malignancies	29	1.42%
Non-Hodgkin lymphoma (NHL)	29	1.42%
Breast cancer	28	1.37%
Other metabolic indications	28	1.37%
General inflammatory disorders	27	1.32%
Ovarian cancer	27	1.32%
Amyotrophic lateral sclerosis (ALS)	26	1.27%
Melanoma	26	1.27%
Leukaemia, acute myeloid (AML)	23	1.13%
Parkinson's disease	21	1.03%
General eye disorders	18	0.88%
Wet age-related macular degeneration (AMD)	18	0.88%
Colorectal cancer	17	0.83%
Pancreatic cancer	17	0.83%
Sickle cell disease	17	0.83%
Gram negative infections	16	0.78%

Only Massachusetts-headquartered company pipelines are included. Source: EvaluatePharma®, July 2020

Changing the Lives of Patients

Drug Development Pipeline

Massachusetts-headquartered companies have developed therapies that treat patient populations of up to



264 million patients IN THE UNITED STATES



2 billion patients AROUND THE WORLD



Appendix

What's in a Number?

Why use the QCEW?

QCEW data is comprised of employment and wages from unemployment insurance (UI) tax reports submitted by employers and is augmented by both BLS worksite reports and the Annual Re-filing Survey (ARS), which surveys one quarter of all private-sector establishments each year. The QCEW data is available on a more timely basis than the CBP and is directly related to the state's ES-202 data, providing an additional, ongoing corroborative source.

What is considered "biopharma" employment?

Using the North American Industry Classification System (NAICS), with which QCEW data is reported, MassBio has determined that several NAICS classifications can be considered part of the biotechnology and pharmaceutical industry. However, only in certain cases can the industry claim 100% of any one NAICS code. MassBio determined that a percentage of some industry classifications could be used in estimating overall industry employment. In some cases, the percentage determination for certain industry codes was based on reports developed by other organizations. The following NAICS codes are utilized:

NAICS 3254: Pharmaceutical MFG, including Biologics (100%)
NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology) (100%)
NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (27% in 2017 and beyond, 22% for 2016 and prior.)
NAICS 541713 Research and Development in Nanotechnology (22%)
NAICS 54176: Analytical Laboratory Instrument MFG (30%)
NAICS 54138: Testing Laboratories (9%)
NAICS 622: Hospitals (4.5%)
NAICS 61131: Universities (1.9%)
NAICS 621511: Medical Testing Laboratories (100%)

As of 2017 data, NAICS 541711, Research and Development in Biotechnology and NAICS 541712, R&D in Physical, Engineering, and Life Sciences (except biotech) have been replaced by 541714 and 541715 respectively. NAICS 541715 was created from parts of the previous NAICS 541711 and NAICS 541712 and now stands alone in the 2017 data.

NAICS 4242, Drug merchant wholesalers, is no longer included in any current or annual employment figures. NAICS 621511, Medical Laboratories, is included. Prior to 2013, we omitted Medical Laboratories, as these laboratories are health care services related, providing services to the medical delivery and patient care system, rather than the Biopharma research development and manufacturing industry. We now acknowledge that Medical Laboratories are closely connected to the Biopharma industry, requiring similar capacity and skills found in the Biopharma industry.



About Us

MassBio's mission

is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system, and improve patient lives. MassBio represents the premier global life sciences and healthcare hub, with 1,300+ members dedicated to preventing, treating, and curing diseases through transformative science and technology that brings value and hope to patients. Founded in 1985, MassBio works to advance policy and promote education, while providing member programs, events, industry information, and services.



MassBio.org • 617.674.5100 MassBio HQ 700 Technology Square, 5th Floor • Cambridge, MA 02139

MassBio West 240 Thatcher Road Amherst, MA 01003 MassBio North

Beverly, MA 01915

100 Cummings Center, Suite 222-F

MassBio Central 60 Prescott Street Worcester, MA 01605



As the premier source of information on life sciences in Massachusetts, MassBio tracks industry statistics over time and issues an overview Industry Snapshot each year.

For more information, contact

Elizabeth Steele Vice President, Programs & Global Affairs Elizabeth.Steele@massbio.org MassBio.org



